about
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancerThe European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsImportance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodiesThe Concept of Hormesis in Cancer Therapy - Is Less More?Immune Checkpoint Blockade in Cancer TherapyAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsAdoptive cell therapies for glioblastomaIn vivo imaging of therapy-induced anti-cancer immune responses in humans.The blockade of immune checkpoints in cancer immunotherapyValidation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerationsMoving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancerImmunotherapy response assessment in neuro-oncology: a report of the RANO working groupA quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trialCirculating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical studyCancer immunotherapy via dendritic cellsCancer immunotherapy comes of ageIntegrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Current clinical trials testing the combination of immunotherapy with radiotherapy.HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.Response Evaluation of Chemotherapy for Lung Cancer.Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancerThe feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancerRetrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer.Immunotherapy for the treatment of prostate cancer.The immuno-oncology framework: Enabling a new era of cancer therapy.Awareness and understanding of cancer immunotherapy in Europe.Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.Immune checkpoint inhibitors in NSCLC.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring.
P2860
Q22001066-289EEB09-D097-4698-A28D-AF3A3D6F2554Q26738677-93C1BA05-A150-4F36-97D3-E44A59848B76Q26775034-1160FC3C-D8EE-4C5C-8643-A6409A6D3302Q26800519-0F02F39E-C05E-4755-ABF5-E5B4B2EA1EEAQ26830509-866AE499-AC5B-42E0-A55B-CA36B453491FQ27004178-F4E76DF0-9778-4EF3-BD7C-E2A30120D725Q27008070-65F11078-36E9-405C-95F0-651A2DC8E8E2Q27026836-EF8C7E4A-D4A4-46E9-8040-049A6DD979BEQ27030863-F6C98A0B-1090-4A32-8A75-BE7C316B920AQ27693338-9BC4218D-CF72-4CB7-9942-4D3DBD1951C9Q27860852-510448F6-83A4-4EB0-8B5A-A98FE3A97BA6Q28066738-598B3335-0891-4360-BE44-46D330EBDD86Q28072004-5556BCD9-13A0-4571-B3BA-4DCFE8D8B5F9Q28083009-B423D2C2-C181-47BC-BEC8-48E12772C42DQ28088679-6613FEAC-A21A-4AD8-B95C-BD1419B999CDQ28535476-D1FD9BF8-F577-4389-B2C7-D0C3B0E4476FQ29615444-A2A9A641-5F72-469E-9C20-234DC2F41E96Q29619918-EEF1C918-01EC-4E22-A2C7-1F01647CD659Q30275792-088EB0F0-25DB-4BA3-987E-06751F50BA45Q30277291-79C026B3-906B-4769-946B-71B4918A04BCQ30356447-0F91FDCA-A210-44E4-87F6-B1E70ED79BCDQ30538743-51BE6574-0837-421F-8D39-9B174C145F80Q30620607-362FCFE4-8E2C-4D65-A0AA-5A8193C39254Q30651792-711FDC8D-F54F-4268-A4FA-04E8119A0AFAQ33427019-3FF78063-943B-4ACC-B9E6-FED2AFD8A94EQ33567345-5BF4EB03-81C7-4A59-B3F8-DC9860467EADQ33643902-958001D9-D77A-4A27-A823-6A65DBD3CBF0Q33658400-2C02DAD7-2439-448B-B8FC-91302BBCBB68Q33845393-FE4BA3AF-812A-4719-9D09-D1D8D9494901Q33909892-73F0FA74-2C74-4639-A0C9-FCC0A69A413AQ33939202-91E56E61-BB79-45EA-B8E8-1E9CCCB924F1Q34119366-E75D6EB4-2210-4CB7-9E07-3A627F24C060Q34186928-FAF9DFE0-6793-4BD5-8D26-99AA19704B8EQ34284462-D0E3941E-9BD4-402F-AE08-DA5FF689ED57Q34291043-3EE1B658-70D6-4DFC-9A55-D6C6D7C3F8F1Q34306503-821020E7-2D64-4287-8B41-FE4DDDDEC270Q34347631-530112ED-DF5A-4E42-9069-19EA86018C0AQ34437570-F1B88E96-0004-46E7-9658-EF48408CC5FDQ34485950-598C0452-6173-4784-B29E-3EE7E5ECECAEQ34522294-155002B3-EF39-4407-A7F0-6AAF39F30453
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Improved endpoints for cancer immunotherapy trials
@ast
Improved endpoints for cancer immunotherapy trials
@en
Improved endpoints for cancer immunotherapy trials
@nl
type
label
Improved endpoints for cancer immunotherapy trials
@ast
Improved endpoints for cancer immunotherapy trials
@en
Improved endpoints for cancer immunotherapy trials
@nl
prefLabel
Improved endpoints for cancer immunotherapy trials
@ast
Improved endpoints for cancer immunotherapy trials
@en
Improved endpoints for cancer immunotherapy trials
@nl
P2093
P2860
P921
P3181
P356
P1476
Improved endpoints for cancer immunotherapy trials
@en
P2093
Alexander M M Eggermont
Aparna Anderson
Brent Blumenstein
F Stephen Hodi
Jedd Wolchok
Rachel Humphrey
Ramy Ibrahim
Sylvia Janetzki
P2860
P304
P3181
P356
10.1093/JNCI/DJQ310
P407
P5008
P577
2010-09-22T00:00:00Z